A comprehensive view of Amneal Pharmaceuticals LLC. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Amneal gets FDA approval for injectable calcium gluconate in sodium chloride, 1000 mg/50 mL and 2000 mg/100 mL, a drug on the FDA shortage list; the firm also received a Competitive Generic Therapy approval designation with 180-day exclusivity

FDA denies approval for Amneal's IPX203, an oral formulation to treat Parkinson’s disease due to inadequate safety data; the rejection affects Amneal’s goal for a midyear launch with potential peak sales opportunity of US$500M in the US

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count